Laquinimod, a once-daily oral drug in development for the treatment of relapsing-remitting multiple sclerosis

Expert Review of Clinical Pharmacology

Volumn 5, Issue 3, 2012, Pages 245-256

  Brück, Wolfgang ^a   Zamvil, Scott S ^b  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

disability; immunomodulation; neuroprotection; oral treatment; RRMS

Indexed keywords

BETA1A INTERFERON; FINGOLIMOD; FUMARIC ACID DIMETHYL ESTER; GLATIRAMER; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LAQUINIMOD; LEFLUNOMIDE; MITOXANTRONE; NATALIZUMAB; PLACEBO; QUINOLINE; ROQUINIMEX; TERIFLUNOMIDE;

ACUTE DISEASE; ALLERGIC ENCEPHALOMYELITIS; BLOOD PRESSURE; BRAIN ATROPHY; CANCER RISK; CARDIOVASCULAR DISEASE; CELL PROLIFERATION; CELL VIABILITY; CHRONIC DISEASE; CLINICAL TRIAL (TOPIC); DEMYELINATION; DIARRHEA; DISABILITY; DISEASE COURSE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; ENCEPHALOMYELITIS; EXPANDED DISABILITY STATUS SCALE; GASTROINTESTINAL DISEASE; HERPES VIRUS INFECTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IMMUNOMODULATION; INFLAMMATION; LIVER FAILURE; MULTIPLE SCLEROSIS; NAUSEA; NERVE DEGENERATION; NEURITIS; NONHUMAN; PARALYSIS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RETINA MACULA EDEMA; REVIEW; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE; WHOLE BODY AUTORADIOGRAPHY;

ADMINISTRATION, ORAL; ANIMALS; CLINICAL TRIALS AS TOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; HUMANS; MICE; MODELS, ANIMAL; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; QUINOLONES;

EID: 84861427775     PISSN: 17512433     EISSN: 17512441     Source Type: Journal    
DOI: 10.1586/ecp.12.12     Document Type: Review

References (41)

1. Stadelmann C. Multiple sclerosis as a neurodegenerative disease: pathology, mechanisms and therapeutic implications. Curr. Opin. Neurol. 24(3), 224-229 (2011).
2. Lassmann H. Pathophysiology of inflammation and tissue injury in multiple sclerosis: what are the targets for therapy. J. Neurol. Sci. 306(1-2), 167-169 (2011).
3. Rieckmann P, Toyka KV. Escalating immunotherapy of multiple sclerosis. Austrian-German-Swiss multiple sclerosis therapy consensus group (MSTCG). Eur. Neurol. 42(3), 121-127 (1999).
4. Nicholas R, Giannetti P, Alsanousi A, Friede T, Muraro PM. Development of oral immunomodulatory agents in the management of multiple sclerosis. Drug Des. Devel. Ther. 5, 255-274 (2011).
5. Conway D, Cohen JA. Emerging oral therapies in multiple sclerosis. Curr. Neurol. Neurosci. Rep. 10(5), 381-388 (2010).
6. Cohen JA, Chun J. Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis. Ann. Neurol. 69(5), 759-777 (2011).
7. Mehling M, Brinkmann V, Antel J et al. FTY720 therapy exerts differential effects on T-cell subsets in multiple sclerosis. Neurology 71(16), 1261-1267 (2008).
8. Kappos L, Radue EW, O'Connor P et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N. Engl. J. Med. 362(5), 387-401 (2010).
9. Cohen JA, Barkhof F, Comi G et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N. Engl. J. Med. 362, 402-415 (2010).
10. GILENYA®, package insert. Novartis Pharma Stein AG, Stein, Switzerland (2010).
11. Khari B, Barkhof F, Comi G et al.; TRANSFORMS Study Group. Comparison of fingolimod with interferon-b-1a in relapsing-remitting multiple sclerosis: a randomized extension of the TRANSFORMS study. Lancet Neurol. 10(6), 520-529 (2011).
12. Hohlfeld R, Barkhof F, Polman C. Future clinical challenges in multiple sclerosis: relevance to sphingosine 1-phosphate receptor modulator therapy. Neurology 76, S28-S37 (2011).
13. Miller A, O'Connor P, Wolinsky JS et al. Clinical and MRI outcomes from a Phase III trial (TEMSO) of oral teriflunomide in multiple sclerosis with relapses. Program and Abstracts of the 63rd Annual Meeting of the American Academy of Neurology. Honolulu, HI, USA, 9-16 April 2011 (Abstract 545).
14. Warnke C, Meyer zu Hörste G, Hartung HP, Stüve O, Kieseier BC. Review of teriflunomide and its potential in the treatment of multiple sclerosis. Neuropsychiatr. Dis. Treat. 5, 333-340 (2009).
15. Claussen MC, Korn T. Immune mechanisms of new therapeutic strategic in MS-teriflunomide. Clin. Immunol. 142(1), 49-56 (2012).
16. Linker RA, Lee DH, Ryan S et al. Fumaric acid esters exert neuroprotective effects in neuroinflammtion via activation of the Nrf2 antioxidant pathway. Brain 134(Pt 3), 678-692 (2011).
17. Jonsson S, Andersson G, Fex T et al. Synthesis and biological evaluation of new 1,2-dihydro-4-hydroxy-2-oxo-3-quinolinecarboxamides for treatment of autoimmune disorders: structure-activity relationship. J. Med. Chem. 47(8), 2075-2088 (2004).
18. Polman C, Barkhof F, Sandberg-Wollheim M, Linde A, Nordle O, Nederman T. Treatment with laquinimod reduces development of active MRI lesions in relapsing MS. Neurology 64(6), 987-991 (2005).
19. Comi G, Pulizzi A, Rovaris M et al. Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomized, double-blind, placebo-controlled Phase IIb study. Lancet 371(9630), 2085-2092 (2008).
20. Comi G, Jeffery D, Kappos L et al. Placebo-controlled trial of oral laquinimod for multiple sclerosis. N. Engl. J. Med. 366(11), 1000-1009 (2012).
21. Brück W, Wegner C. Insight into the mechanism of laquinimod action. J. Neurol. Sci. 306(1-2), 173-179 (2011).
22. Steinman L, Zamvil SS. Virtues and pitfalls of EAE for the development of therapies for multiple sclerosis. Trends Immunol. 26(11), 565-571 (2005).
23. Brunmark C, Runstrom A, Ohlsson L et al. The new orally active immunoregulator laquinimod (ABR-215062) effectively inhibits development and relapses of experimental autoimmune encephalomyelitis. J. Neuroimmunol. 130(1-2), 163-172 (2002).
24. Yang JS, Xu LY, Xiao BG, Hedlund G, Link H. Laquinimod (ABR-215062) suppresses the development of experimental autoimmune encephalomyelitis, modulates the Th1/Th2 balance and induces the Th3 cytokine TGF-b in Lewis rats. J. Neuroimmunol. 156(1-2), 3-9 (2004).
25. Wegner C, Stadelmann C, Pförtner R et al. Laquinimod interferes with migratory capacity of T cells and reduces IL-17 levels, inflammatory demyelination and acute axonal damage in mice with experimental autoimmune encephalomyelitis. J. Neuroimmunol. 227(1-2), 133-143 (2010).
26. Zou LP, Abbas N, Volkmann I et al. Suppression of experimental autoimmune neuritis by ABR-215062 is associated with altered Th1/Th2 balance and inhibited migration of inflammatory cells into the peripheral nerve tissue. Neuropharmacology 42(5), 731-739 (2002).
27. AA32235. Laquinimod sodium: 4-week oral (gavage) immunotoxicity study in the Sprague Dawley rat. MDS Pharma Services, France (2007) (Final Report).
28. HeartTx/Teva-LQ/Jun06. Laquinimod does not result in prolongation of heart survival in a model of allogeneic heterotopic rat heart transplants. Teva Pharmaceutical Industries, Israel (2006) (Final Report).
29. Gurevich M, Gritzman T, Orbach R, Tuller T, Feldman A, Achiron A. Laquinimod suppress antigen presentation in relapsing-remitting multiple sclerosis: in vitro high-throughput gene expression study. J. Neuroimmunol. 221(1-2), 87-94 (2010).
30. Sättler MB, Togni M, Gadjanski I et al. Strain-specific susceptibility for neurodegeneration in a rat model of autoimmune optic neuritis. J. Neuroimmunol. 193(1-2), 77-86 (2008).
31. Sühs KW. Effects of laquinimod on axon degeneration in autoimmune optic neuritis. Mult. Scler. 13, S7-S273, P835 (2007).
32. Thöne J, Ellrichmann G, Seubert S et al. Modulation of autoimmune demyelination by laquinimod via induction of brain-derived neurotrophic factor. Am. J. Pathol. 180(1), 267-274 (2012).
33. Tuvesson H, Hallin I, Ellman M et al. In vitro metabolism and in vivo pharmacokinetics of quinoline 3-carboxamide derivatives in various species. Xenoboiotica 35(3), 293-304 (2005).
34. Tuvesson H, Hallin I, Persson R et al. Cytochrome P450 3A4 is the major enzyme responsible for the metabolism of laquinimod, a novel immunomodulator. Drug Metab. Dispos. 33(6), 866-872 (2005).
35. Comi G, Abramsky O, Arbizu T et al. Oral laquinimod in patients with relapsing-remitting multiple sclerosis: 36 weeks double-blind active extension of the multicenter, randomized, double-blind, parallel-group placebo-controlled study. Mult. Scler. 16(11), 1360-1366 (2010).
36. Comi G, Abramsky O, Arbizu T et al. Long-term open extension of oral laquinimod in patients with relapsing multiple sclerosis shows favorable safety and sustained low relapse rate and MRI activity. Presented at: The 25th Congress of the European Committee for Treatment and Research in Multiple Sclerosis. Düsseldorf, Germany, 9-12 September 2009.
37. Thöne J, Gold R. Laquinimod: a promising oral medication for the treatment of relapsing-remitting multiple sclerosis. Expert Opin. Drug Metab. Toxicol. 7(3), 365-370 (2011).
38. Vollmer TL, Sörensen PS, Arnold DL; on behalf of the BRAVO study group. A placebo-controlled and active comparator Phase III trial (BRAVO) for relapsing-remitting multiple sclerosis: Presented at: The 27th Congress of the European Committee for Treatment and Research in Multiple Sclerosis. Amsterdam, The Netherlands, 19-22 October 2011.
39. Kurtzke JF. Rating neurological impairment in multiple sclerosis: an Expanded Disability Status Scale (EDSS). Neurology 33, 1444-1452 (1983).
40. Janssen HL, Meinardi JR, Vleggaar FP et al. Factor V leiden mutation, prothrombin gene mutation, and deficiencies in coagulation inhibitors associated with Budd-Chiari syndrome and portal vein thrombosis: results of a case-control study. Blood 96(7), 2364-2368 (2000).
41. Deltenre P, Denninger MH, Hillaire S et al. Factor V leiden related Budd-Chiari syndrome. Gut 48(2), 264-268 (2001).